Phreesia (PHR) Stock Price, News & Analysis

+0.72 (+3.21%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
386,052 shs
Average Volume
517,033 shs
Market Capitalization
$1.30 billion
P/E Ratio
Dividend Yield
Price Target

Phreesia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
36.7% Upside
$31.62 Price Target
Short Interest
3.83% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.14mentions of Phreesia in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.91 M Sold Last Quarter
Proj. Earnings Growth
From ($1.48) to ($1.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

87th out of 909 stocks

Business Services, Not Elsewhere Classified Industry

15th out of 86 stocks

PHR stock logo

About Phreesia Stock (NYSE:PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

PHR Stock Price History

PHR Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Truist Financial Reaffirms Their Buy Rating on Phreesia (PHR)
Phreesia gets new technology chief
Stock Market News for Mar 18, 2024
See More Headlines
Receive PHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Business services, not elsewhere classified
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$356.30 million
Book Value
$4.52 per share


Free Float
Market Cap
$1.30 billion
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Phreesia stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHR shares.
View PHR analyst ratings
or view top-rated stocks.

What is Phreesia's stock price target for 2024?

14 analysts have issued 1 year price targets for Phreesia's stock. Their PHR share price targets range from $23.00 to $40.00. On average, they expect the company's share price to reach $31.62 in the next year. This suggests a possible upside of 36.7% from the stock's current price.
View analysts price targets for PHR
or view top-rated stocks among Wall Street analysts.

How have PHR shares performed in 2024?

Phreesia's stock was trading at $23.15 at the beginning of 2024. Since then, PHR shares have decreased by 0.1% and is now trading at $23.13.
View the best growth stocks for 2024 here

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024.
View our PHR earnings forecast

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) released its earnings results on Thursday, March, 14th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. The business had revenue of $95 million for the quarter, compared to analysts' expectations of $93.52 million. Phreesia had a negative trailing twelve-month return on equity of 53.33% and a negative net margin of 38.42%. The company's quarterly revenue was up 24.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.72) EPS.

What guidance has Phreesia issued on next quarter's earnings?

Phreesia updated its FY 2025 earnings guidance on Thursday, March, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $424.0 million-$434.0 million, compared to the consensus revenue estimate of $428.1 million.

What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).

When did Phreesia IPO?

Phreesia (PHR) raised $127 million in an IPO on Thursday, July 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray acted as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's stock is owned by many different retail and institutional investors. Top institutional investors include Arcadia Investment Management Corp MI (0.14%), Moody National Bank Trust Division (0.13%), WoodTrust Financial Corp (0.05%) and Diversified Trust Co (0.02%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, David Linetsky, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub and Randy Rasmussen.
View institutional ownership trends

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PHR) was last updated on 4/23/2024 by Staff

From Our Partners